New study tracks epidiolex use in pregnancy for baby safety
NCT ID NCT06113237
First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study follows pregnant women who have taken Epidiolex (a cannabidiol medicine for seizures) to see if it affects pregnancy outcomes or the baby's health up to 12 months after birth. Researchers will track complications like birth defects, miscarriage, and preterm delivery. The goal is to better understand any risks, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epidiolex (cannabidiol oral solution)
What this could lead to
If successful, this study could provide important safety information about using Epidiolex during pregnancy, helping doctors and patients make informed decisions.
What could go wrong
This is an observational study with only 50 participants, so results may not apply to everyone. It is designed to gather data, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
United Biosource LLC
RECRUITINGMorgantown, West Virginia, 26508, United States
-
Vivantes Humboldt-Klinikum Klinik für Neurologie
RECRUITINGBerlin, 13509, Germany